IDX184

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Hepatitis CChronic Hepatitis C (HCV)Chronic Hepatitis C InfectionHepatitis CHepatitis C, Chronic

Phase 1

Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)

CompletedNCT00730431

Merck Sharp & Dohme LLCHepatitis C

Start: 2008-07-31End: 2008-10-31Target: 48Updated: 2015-04-23

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

CompletedNCT00807001

Merck Sharp & Dohme LLCChronic Hepatitis C (HCV)

Start: 2008-12-31End: 2009-07-31Updated: 2016-08-19

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

CompletedNCT01157104

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2010-06-30End: 2010-08-31Updated: 2016-01-22

Phase 2

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

CompletedNCT01011166

Merck Sharp & Dohme LLCChronic Hepatitis C Infection

Start: 2009-11-30End: 2010-07-31Updated: 2015-04-23

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

CompletedNCT01371604

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-07-31End: 2014-10-31Updated: 2015-02-06